What V-Dalgin Treats: Main Uses and Benefits

V-Dalgin may be part of symptomatic management across several domains of acute patient discomfort and is relevant when symptoms become more noticeable. The active ingredient is commonly used to help with acute pain, fever, and colic pain in countries where it is approved.

The medication is commonly used to help with symptoms related to moderate-to-severe pain, cramp-like visceral pain caused by smooth muscle spasm, and symptoms related to high fever. It is applied across domains where additional symptomatic support is needed to manage the intensity of these manifestations.

“The medication is helpful in situations where pain and fever are present together, symptoms related to systemic imbalance, and is used across domains where short-term symptom management is appropriate.”

V-Dalgin is relevant in clinical settings that involve acute or unstable symptom patterns, such as renal or biliary colic, postoperative discomfort, and certain types of headaches. Providing supportive relief helps patients cope more steadily with difficult episodes and assists with maintaining functional stability.

---

Quick Fact: Symptomatic Support for Visceral Spasm

V-Dalgin is commonly used to help with symptoms that create noticeable physiological strain, such as cramp-like pain linked to organ-specific functional stress.

---

Who Can and Cannot Use V-Dalgin?

The eligibility for V-Dalgin (Sodium Metamizole) is strictly defined by regulatory authorities based on a patient’s medical history, age, and physiological status.

Absolute Contraindications (Must Not Use): Use is strictly prohibited for patients with a known history of agranulocytosis or severe hypersensitivity reactions to metamizole or other pyrazolone derivatives. It is also contraindicated in individuals with impaired bone marrow function, diseases of the haematopoietic system, or acute hepatic porphyria. Use is absolutely prohibited in infants below 3 months of age or weighing less than 5 kg. V-Dalgin is contraindicated during the third trimester of pregnancy.

Restricted or Conditional Use: The medicine is generally advised against or limited to conditional use in patients with existing renal impairment or hepatic impairment, as well as in geriatric patients. Use is also not recommended during the first and second trimesters of pregnancy or while breastfeeding.

Approved Populations: V-Dalgin is permitted for use in adults and adolescents aged 15 years and older, and in children aged 3 months to 14 years who meet the minimum weight requirements.

V-Dalgin Interactions with other medicines and products

---

Pharmacokinetic (PK) Interactions

The official regulatory profile documents that V-Dalgin (Sodium Metamizole) is an inducer of specific metabolic enzymes, notably CYP3A4, CYP2B6, and CYP2C19. This pharmacokinetic interaction results in a potential reduction in plasma concentrations of medicines that are substrates for these enzymes.

Cyclosporine is an essential interacting medicinal product; co-administration may significantly reduce its plasma concentration, requiring mandatory therapeutic drug monitoring as specified in labeling. A similar potential reduction in plasma levels is associated with co-administration of Bupropion, Methadone, Sertraline, and Midazolam.

---

Pharmacodynamic (PD) Interactions and Restrictions

The regulatory data also describes several pharmacodynamic interactions that alter the effect of co-administered agents:

• Antiplatelet Agents: Co-administration with low-dose Acetylsalicylic acid (aspirin) interferes with its antiplatelet effect. To mitigate this pharmacodynamic interference, a separation of administration is required in regulatory guidance.
• Additive Risk: V-Dalgin's co-administration with other NSAIDs may increase the risk of nephrotoxicity. Additionally, combining V-Dalgin with myelosuppressive drugs is associated with an increased risk of severe myelosuppression.
• Reduced Efficacy: V-Dalgin may officially reduce the antihypertensive activities of certain blood pressure-lowering agents, such as Aliskiren and Acebutolol.

No explicit interaction with food, alcohol, or specific herbal products is formally documented in the official prescribing information.

Central Regulation of Nociception and Temperature Signals

This core mechanism involves V-Dalgin's active metabolites acting within the Central Nervous System (CNS) to modulate pathways governing nociception and temperature control. The metabolites inhibit enzymes like Cyclooxygenase-3 ( COX-3) in the hypothalamus to limit the synthesis of Prostaglandin E2 ( PGE2), resulting in the modulation of the thermal set point. Simultaneously, it enhances the descending inhibitory pain control system by activating CB1 and kappa-opioid receptors, which results in the central reduction of nociceptive signal transmission.

Direct Modulation of Smooth Muscle Tone

V-Dalgin also influences the physiology of involuntary smooth muscle tissues found in visceral organs. This mechanism is achieved through the modulation of ion channels and intracellular calcium flux. By activating ATP-sensitive Potassium Channels (KATP) and inhibiting cascades that control internal calcium release, the drug causes hyperpolarization and relaxation of the hypercontracted muscle fibers.

Intrinsic Multi-Modal Pharmacodynamic Synergy

The overall physiological profile of V-Dalgin is shaped by the simultaneous engagement of these mechanisms—central enzyme inhibition, central receptor modulation, and peripheral ion channel activation. This intrinsic synergy results in the modulation of nociceptive signaling, thermoregulation, and muscle tone via distinct but complementary pathways, leading to a multi-system physiological modulation.

Official Administration Instructions

V-Dalgin is administered via the oral route and is available in two forms: Oral Drops for infants and children, and Concentrated Syrup for adults and adolescents. The instructions specify that the medicine should be taken with a glass of water, and intake is permitted either before or after a meal.

Dosing Schedule and Frequency

The correct dose is determined by the patient’s age and body weight. All doses, regardless of the patient group, are to be administered up to 3 times a day with a strict interval of 6–8 hours between doses. The total daily dose must not exceed the maximum limit.

Patient Group	Body Weight (kg)	Dosage Form	Single Dose (Drops or mL)	Maximum Frequency
Infants	5–8 kg	Oral Drops	2–4 drops	3 times daily
Children	9–53 kg	Oral Drops	3–35 drops (range varies by weight)	3 times daily
Adults/Adolescents	ge 53 kg	Conc. Syrup	2–4 mL	3 times daily
Adults/Adolescents	ge 53 kg	Oral Drops	20–40 drops	3 times daily

Note: The concentrated syrup is not intended for use in children; the drops should be used for patients under 15 years old. The drops are not for infants weighing less than 5 kg.

Procedural and Course Duration Rules

If a dose is missed, do not take a double dose to compensate; continue the treatment regimen as originally scheduled. The medicine must not be used frequently or for prolonged periods without consulting a doctor. If treatment is required for an extended period, medical advice is required.

The research landscape for V-Dalgin’s active ingredient, Sodium Metamizole, has been studied for conditions involving fluctuating or unstable symptoms. The evidence is derived from short-term controlled clinical trials and systematic reviews, exploring outcomes related to physical discomfort and systemic or functional imbalance (fever). Findings describe patterns observed in the studies conducted in specific patient groups.

---

Evidence for Managing Acute and Moderate-to-Severe Pain

Research for V-Dalgin was studied for conditions associated with acute or disruptive episodes, such as post-operative discomfort. The majority of evidence stems from short-term Randomized Controlled Trials (RCTs) evaluated in hospitalized and general adult cohorts. Studies examined outcomes related to patient-reported discomfort, such as changes in pain intensity scores, and the need for secondary pain medication. Data show patterns related to short observation periods, often hours or days after administration. Research has also explored its use in specific conditions like cramp-like visceral pain, though dedicated, high-quality RCTs in that area are scarce.

---

Evidence for Managing High Fever (Antipyretic Use)

V-Dalgin was studied for conditions involving systemic or functional imbalance (fever). RCTs and systematic reviews have been evaluated in research exploring short-term symptom changes, with a notable focus on pediatric populations. Studies explored the rate and magnitude of the change in body temperature and the persistence of the observed change. Comparative evidence is lacking for its use specifically in general adult populations with fever.

---

Research Limitations and Areas of Uncertainty

A few key areas of uncertainty remain in the overall evidence landscape. Follow-up durations were limited in the majority of V-Dalgin studies, concentrating on single-dose or acute administration. Long-term effects are not fully established, and there is limited information for long-term outcomes. While pediatric populations were evaluated in numerous RCTs for fever, data for other groups, such as pregnant or breastfeeding populations, remain insufficient. Furthermore, evidence quality varies across older studies, and the need for new evidence is noted in systematic reviews.

Key Studies & References EMA Assessment report - Referral under Article 31 of Directive 2001/83/EC metamizole-containing medicinal products INN

Common questions about V-Dalgin (FAQ)

---

Q: How quickly does V-Dalgin start working?

A: V-Dalgin (Metamizole) is rapidly converted into its main active substance after oral intake. Official drug information indicates that the maximum concentration of this active substance in the blood is typically reached within 1.4 to 2.0 hours. This process suggests a relatively quick conversion to the active component, which supports its use for acute symptom management.

---

Q: How long does the effect of a single dose of V-Dalgin last?

A: Regulatory guidelines specify that doses should be administered at intervals of 6 to 8 hours. This suggested interval provides an indication of the expected duration of the drug's effect, though individual experience may vary.

---

Q: What is the maximum daily dose for V-Dalgin?

A: Official product information defines a maximum daily limit for the active ingredient, Sodium Metamizole, for safety. Patients should refer to their local product labeling or consult a healthcare professional for specific dosing instructions based on their local regulatory guidance.

---

Q: Can V-Dalgin be used to manage chronic pain conditions?

A: Official regulatory documents generally recommend V-Dalgin for short-term treatment only for acute symptoms. For extended treatment periods, regulatory guidance indicates that ongoing monitoring, such as specific periodic blood tests (hematological monitoring), may be necessary.

---

Q: Is V-Dalgin safe to use during pregnancy?

A: Official product information states that Metamizole is contraindicated during the third trimester of pregnancy due to potential risks to the fetus. While it is not strictly prohibited earlier, its use is generally not recommended during the first and second trimesters.

---

Q: What should I do if I accidentally take too much V-Dalgin?

A: If an overdose of V-Dalgin is suspected, immediate medical attention is necessary. Regulatory documents state that the management of an overdose may involve supportive measures and procedures for gastric decontamination.

---

Q: What are the common side effects of V-Dalgin?

A: Common adverse events noted in clinical experience and regulatory documents can include general discomfort such as nausea, vomiting, dizziness, headache, or abdominal pain. Any experienced side effects should be reviewed with a healthcare professional.

---

Q: What are the symptoms of agranulocytosis I should watch for?

A: Agranulocytosis is a rare but serious blood disorder associated with this medicine. If symptoms of agranulocytosis occur, treatment should be stopped immediately and urgent medical care is required. Key symptoms include fever, chills, a sore throat, or painful ulcers on the moist membranes of the body (mucosa).

---

Q: Does V-Dalgin cause drowsiness or affect my ability to drive?

A: Official labeling mentions that adverse reactions such as dizziness (vertigo), fatigue, or temporary vision problems may occur. If these effects occur, activities requiring mental alertness, such as driving or operating heavy machinery, may need to be postponed.

Storage and Disposal Requirements for V-Dalgin

Official regulatory documents define strict environmental and stability rules for V-Dalgin (Sodium Metamizole liquid preparations).

Storage Conditions and Stability

The medicine must be stored at a temperature below 25°C and must not be frozen. The V-Dalgin Concentrated Syrup for Adults requires an additional constraint to be stored in a dark place.

Formulation	Post-Opening Stability Period
Concentrated Syrup	Up to 1 month from first opening
Oral Drops	Up to 6 months from first opening

Handling and Disposal

The most important handling and disposal requirements state that the medicine must be kept out of the reach of children and/or infants to prevent poisoning. Furthermore, the product must not be used after the expiration date shown on the original packaging.